Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11

You may also be interested in...

Lupin, Merck KGaA In Advanced Talks For Complex Generics Deal

Changing landscape of the global pharmaceutical market is likely bringing India’s Lupin and German’s Merck closer. Industry sources say a deal is close to being announced.

India’s SPARC Scouts For Allies As Pipeline Drugs Advance, Higher Expenses Lurk

Sun Pharma Advanced Research Company (SPARC) briefed analysts about its pipeline of drugs under development. While candidates seem to have showed positive results, SPARC will eye partnering prospects to enrich and grow its pipeline.

Sun Pharmaceutical’s SPARC Unit Hopes To Kindle India Research Pipeline

Sun Pharma’s research unit SPARC shared an update of its research pipeline, but analysts are short on excitement, owing mostly to delays on timelines.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts